Does the media refer more to ACAD or ASND?

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 6 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.64 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or ACAD?

In the previous week, BridgeBio Pharma had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 10 mentions for BridgeBio Pharma and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat BridgeBio Pharma's score of 0.72 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or ACAD?

In the previous week, Elanco Animal Health had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for ACADIA Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.37 beat ACADIA Pharmaceuticals' score of 0.83 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or ACAD?

In the previous week, Axsome Therapeutics had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.61 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or ACAD?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 5 mentions for Summit Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.42 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$25.09 -0.51 (-1.99%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$25.28 +0.18 (+0.74%)

As of 07:30 AM Eastern

Compare

ACAD vs. ASND, BBIO, ELAN, AXSM, and SMMT

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? MarketBeat compares ACADIA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ACADIA Pharmaceuticals include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, ACADIA Pharmaceuticals and ACADIA Pharmaceuticals both had 6 articles in the media. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.64 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals presently has a consensus price target of $32.94, suggesting a potential upside of 31.29%. Ascendis Pharma A/S has a consensus price target of $295.67, suggesting a potential upside of 17.44%. Given ACADIA Pharmaceuticals' higher probable upside, equities research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40
Ascendis Pharma A/S	$865.78M	18.14	-$258M	$8.67	29.04

Ascendis Pharma A/S has a net margin of 57.87% compared to ACADIA Pharmaceuticals' net margin of 34.30%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Summary

ACADIA Pharmaceuticals and Ascendis Pharma A/S tied by winning 8 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

BridgeBio Pharma has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to BridgeBio Pharma's net margin of -124.42%. ACADIA Pharmaceuticals' return on equity of 9.61% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 4 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 10 mentions for BridgeBio Pharma and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat BridgeBio Pharma's score of 0.72 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.50	-$724.93M	-$3.74	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

BridgeBio Pharma presently has a consensus target price of $95.21, indicating a potential upside of 17.89%. ACADIA Pharmaceuticals has a consensus target price of $32.94, indicating a potential upside of 31.29%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Elanco Animal Health's net margin of -4.95%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

In the previous week, Elanco Animal Health had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Elanco Animal Health and 6 mentions for ACADIA Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.37 beat ACADIA Pharmaceuticals' score of 0.83 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health presently has a consensus target price of $28.55, indicating a potential upside of 13.39%. ACADIA Pharmaceuticals has a consensus target price of $32.94, indicating a potential upside of 31.29%. Given ACADIA Pharmaceuticals' higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

ACADIA Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Axsome Therapeutics had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.61 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Axsome Therapeutics' net margin of -26.59%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.86	-$183.17M	-$3.73	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $261.48, indicating a potential upside of 17.97%. ACADIA Pharmaceuticals has a consensus price target of $32.94, indicating a potential upside of 31.29%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Summary

ACADIA Pharmaceuticals beats Axsome Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 5 mentions for Summit Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.42 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus target price of $26.97, suggesting a potential upside of 99.80%. ACADIA Pharmaceuticals has a consensus target price of $32.94, suggesting a potential upside of 31.29%. Given Summit Therapeutics' higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Summit Therapeutics has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.38B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	11.40	20.49	27.07	23.95
Price / Sales	4.01	300.33	515.05	90.33
Price / Cash	28.86	60.31	26.68	47.25
Price / Book	3.46	7.92	10.62	6.14
Net Income	$391M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.57%	-1.09%	-1.26%	-1.82%
1 Month Performance	16.05%	2.56%	1.07%	-1.45%
1 Year Performance	12.61%	42.16%	23.63%	16.32%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.7961 of 5 stars	$25.09 -2.0%	$32.94 +31.3%	+11.2%	$4.38B	$1.07B	11.40	510
ASND Ascendis Pharma A/S	4.4428 of 5 stars	$265.22 -1.9%	$295.67 +11.5%	+48.2%	$16.87B	$814.57M	30.59	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.6033 of 5 stars	$83.08 -3.3%	$94.63 +13.9%	+73.6%	$16.82B	$502.08M	N/A	400
ELAN Elanco Animal Health	3.9173 of 5 stars	$25.13 +1.2%	$28.55 +13.6%	+70.3%	$12.40B	$4.72B	N/A	9,400	News Coverage Positive News
AXSM Axsome Therapeutics	3.9684 of 5 stars	$228.28 -2.4%	$259.05 +13.5%	+98.4%	$12.03B	$638.50M	N/A	380	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Does the media refer more to ACAD or ASND?

Which has more volatility & risk, ACAD or ASND?

Do insiders & institutionals hold more shares of ACAD or ASND?

Do analysts rate ACAD or ASND?

Which has higher valuation and earnings, ACAD or ASND?

Is ACAD or ASND more profitable?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or ACAD?

Is BBIO or ACAD more profitable?

Do institutionals and insiders believe in BBIO or ACAD?

Does the media favor BBIO or ACAD?

Which has preferable valuation and earnings, BBIO or ACAD?

Do analysts rate BBIO or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

Is ELAN or ACAD more profitable?

Does the media prefer ELAN or ACAD?

Do analysts recommend ELAN or ACAD?

Which has more volatility and risk, ELAN or ACAD?

Which has preferable earnings and valuation, ELAN or ACAD?

Do institutionals & insiders believe in ELAN or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Does the media prefer AXSM or ACAD?

Is AXSM or ACAD more profitable?

Do institutionals and insiders believe in AXSM or ACAD?

Which has stronger valuation and earnings, AXSM or ACAD?

Which has more volatility & risk, AXSM or ACAD?

Do analysts recommend AXSM or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Is SMMT or ACAD more profitable?

Do institutionals & insiders have more ownership in SMMT or ACAD?

Which has higher earnings & valuation, SMMT or ACAD?

Does the media prefer SMMT or ACAD?

Do analysts prefer SMMT or ACAD?

Which has more risk and volatility, SMMT or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools